Home LiteratureArticle Details
PMID: 18047684 Published · epublish English Journal Article

Epigenetic regulation of RhoB loss of expression in lung cancer.

BMC cancer ·Vol. 7 ·2007-11-30 ·Pages 220

Mazières J, Tovar D, He B, Nieto-Acosta J, Marty-Detraves C, Clanet C, Pradines A, Jablons D, Favre G

Abstract

RhoB is down-regulated in most lung cancer cell lines and tumor tissues when compared with their normal counterparts. The mechanism of this loss of expression is not yet deciphered. Since no mutation has been reported in the RhoB sequence, we investigated the epigenetic regulation of RhoB expression by analyzing the effect of HDAC inhibitors and methyltransferase inhibitors, by direct sequencing after bisulfite treatment and by methylation specific PCR. We first showed that histone deacetylase (HDAC) inhibitors induce a significant RhoB re-expression in lung cancer cell lines whereas only a slight effect was observed with methyl transferase inhibitors. As promoter methylation is the most common epigenetic process in lung cancer, we performed methylation specific PCR and sequence analysis after bisulfite treatment and demonstrated that RhoB was methylated neither in lung cancer cell lines nor in tumor tissues. We also showed that a variable number of tandem repeats sequences in the 5' region of the RhoB gene was involved in HDAC response. We thus propose that RhoB regulation of expression occurs mainly by histone deacetylation rather than by promoter hypermethylation and that this process can be modulated by specific 5' sequences within the promoter.

MeSH Terms
Azacitidine/analogs & derivatives,pharmacology Base Sequence Carcinoma, Non-Small-Cell Lung/genetics,metabolism,pathology Cell Line, Tumor/chemistry,metabolism,pathology DNA (Cytosine-5-)-Methyltransferases/antagonists & inhibitors DNA Methylation Down-Regulation Enzyme Inhibitors/pharmacology Epigenesis, Genetic Gene Expression Gene Expression Regulation, Neoplastic Gene Silencing Histone Deacetylase Inhibitors Humans Immunoblotting Lung Neoplasms/genetics,metabolism,pathology Promoter Regions, Genetic Reverse Transcriptase Polymerase Chain Reaction Sulfites Tandem Repeat Sequences rhoB GTP-Binding Protein/biosynthesis,genetics
Chemicals
Enzyme Inhibitors Histone Deacetylase Inhibitors Sulfites DNA (Cytosine-5-)-Methyltransferases rhoB GTP-Binding Protein Azacitidine hydrogen sulfite
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Mazières Julien
INSERM U563 - Département Innovation Thérapeutique et Oncologie Moléculaire, F-31052, Toulouse, France. mazieres.j@chu-toulouse.fr
Tovar Daniel
He Biao
Nieto-Acosta Jacobo
Marty-Detraves Claire
Clanet Carine
Pradines Anne
Jablons David
Favre Gilles
References (28)
28 references, click to expand
  1. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters.
    Br J Cancer. 2002 Sep 9;87(6):635-44 PMID: 12237774
  2. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity.
    Mol Cell Biol. 1995 Dec;15(12):6613-22 PMID: 8524226
  3. The ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments.
    J Biol Chem. 1995 Oct 20;270(42):25172-7 PMID: 7559652
  4. Rho proteins and cancer.
    Breast Cancer Res Treat. 2004 Mar;84(1):13-9 PMID: 14999150
  5. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus.
    Nat Genet. 1996 Mar;12(3):309-11 PMID: 8589723
  6. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer.
    Nat Genet. 1999 Jan;21(1):103-7 PMID: 9916800
  7. Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line.
    Oncogene. 2003 Sep 18;22(40):6204-13 PMID: 13679859
  8. RHO-GTPases and cancer.
    Nat Rev Cancer. 2002 Feb;2(2):133-42 PMID: 12635176
  9. RhoB is dispensable for mouse development, but it modifies susceptibility to tumor formation as well as cell adhesion and growth factor signaling in transformed cells.
    Mol Cell Biol. 2001 Oct;21(20):6906-12 PMID: 11564874
  10. RhoB protects human keratinocytes from UVB-induced apoptosis through epidermal growth factor receptor signaling.
    J Biol Chem. 2005 Dec 30;280(52):43257-63 PMID: 16278215
  11. Mechanisms of p16INK4A inactivation in non small-cell lung cancers.
    Oncogene. 1998 Jan 29;16(4):497-504 PMID: 9484839
  12. DNA methylation profiles of lung tumors.
    Mol Cancer Ther. 2001 Nov;1(1):61-7 PMID: 12467239
  13. Differential localization of Rho GTPases in live cells: regulation by hypervariable regions and RhoGDI binding.
    J Cell Biol. 2001 Jan 8;152(1):111-26 PMID: 11149925
  14. Actin' up: RhoB in cancer and apoptosis.
    Nat Rev Cancer. 2001 Nov;1(2):162-8 PMID: 11905808
  15. Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer.
    Cancer Res. 2004 Jul 15;64(14):4717-20 PMID: 15256437
  16. Loss of RhoB expression in human lung cancer progression.
    Clin Cancer Res. 2004 Apr 15;10(8):2742-50 PMID: 15102679
  17. Gene-promoter hypermethylation as a biomarker in lung cancer.
    Nat Rev Cancer. 2004 Sep;4(9):707-17 PMID: 15343277
  18. Cloning of the human RHOB gene promoter: characterization of a VNTR sequence that affects transcriptional activity.
    Genomics. 2003 May;81(5):525-30 PMID: 12706111
  19. RhoB prenylation is driven by the three carboxyl-terminal amino acids of the protein: evidenced in vivo by an anti-farnesyl cysteine antibody.
    Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11626-31 PMID: 11027361
  20. The expression of rho proteins decreases with human brain tumor progression: potential tumor markers.
    Clin Exp Metastasis. 2002;19(1):9-15 PMID: 11918088
  21. Epigenetics in lung cancer: focus on progression and early lesions.
    Chest. 2004 May;125(5 Suppl):119S-22S PMID: 15136457
  22. Suppression of rho B expression in invasive carcinoma from head and neck cancer patients.
    Clin Cancer Res. 2002 Jul;8(7):2225-32 PMID: 12114424
  23. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer.
    Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14133-8 PMID: 14617776
  24. Histone deacetylase 1 mRNA expression in lung cancer.
    Lung Cancer. 2004 Nov;46(2):171-8 PMID: 15474665
  25. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice.
    J Biol Chem. 2000 Jun 16;275(24):17974-8 PMID: 10770919
  26. Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells.
    Exp Cell Res. 2005 Apr 1;304(2):354-64 PMID: 15748883
  27. Association of chromosome 12p genetic polymorphisms with lung adenocarcinoma risk and prognosis.
    Carcinogenesis. 1997 Oct;18(10):1917-20 PMID: 9364000
  28. RhoB is frequently downregulated in non-small-cell lung cancer and resides in the 2p24 homozygous deletion region of a lung cancer cell line.
    Int J Cancer. 2007 Feb 1;120(3):543-51 PMID: 17096327
Article Info
Journal
BMC cancer
Abbr.
BMC Cancer
ISSN
1471-2407
Published
2007-11-30
Epub
2007-00-30
Pages
220
Language
English
Region
England
NLM ID
100967800
PMCID
PMC2222678
Subset
IM
Grants
NCI NIH HHS · R01 CA093708 · United States
NCI NIH HHS · R01 CA093708-03 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com